Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 9,853 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Microbial Colonization Clear all
Completed Phase 4 Interventional

An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

NCT00141284
View directory record Official record
Conditions
HIV Infection, Hepatitis C
Interventions
nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Bakersfield, California • Miami, Florida • Shreveport, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2011 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 4 Interventional

Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis

NCT00000816
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sulfamethoxazole-Trimethoprim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
40
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block for COVID-induced Parosmia

NCT06253806
View directory record Official record
Conditions
COVID-19-Induced Parosmia
Interventions
Stellate Ganglion Block, Placebo Sham Injection
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Not applicable Interventional

Effectiveness of a School-Based Hand Sanitizer Program on Reducing Asthma Exacerbations

NCT00528814
View directory record Official record
Conditions
Asthma
Interventions
Active Hand Sanitizer
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 12 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 26, 2017 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 2 Interventional

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma

NCT00002314
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Ro 24-7429
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

NCT00001021
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
3
States / cities
St Louis, Missouri • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 20, 2026, 7:31 PM EDT
Active, not recruiting Not applicable Interventional

The Cheeky Study: A Novel Delivery System for CAB-RPV LA

NCT05979714
View directory record Official record
Conditions
HIV Infections
Interventions
Patient-centered injection site, Patient-centered adherence support, Provider education, Improved clinic communication strategies
Other · Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 4 Interventional Results available

Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection

NCT01509404
View directory record Official record
Conditions
Cytomegalovirus Disease
Interventions
Valganciclovir, CMV hyperimmune globulin
Drug · Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Not applicable Interventional Results available

Standardized Patients to Measure and Address Intersectional Stigma

NCT04896216
View directory record Official record
Conditions
Hiv, HIV Infections, AIDS
Interventions
Stigma Reduction Intervention
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 20, 2026, 7:31 PM EDT
Not listed Not applicable Interventional

Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens

NCT02764359
View directory record Official record
Conditions
Infection, Sepsis, Obesity
Interventions
IV vancomycin
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study

NCT02933879
View directory record Official record
Conditions
Onychomycosis
Interventions
NVXT topical, Placebo (Vehicle) Topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Jul 20, 2026, 7:31 PM EDT
Recruiting Phase 2 Interventional

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

NCT07244263
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Zasocitinib (Dose A), Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 20, 2026, 7:31 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Bladder Morphology Using 2 Different Catheter Designs

NCT03108079
View directory record Official record
Conditions
Urologic Injuries, Urologic Diseases, Bladder Infection, Urinary Tract Infections, Mucosal Inflammation, Mucosal Infection, Bladder Injury, Catheter-Related Infections, Catheter Complications, Catheter; Infection (Indwelling Catheter), Pelvic Floor Disorders, Urinary Incontinence
Interventions
Cystosure Urinary Access System, Foley Catheter
Device
Lead sponsor
The Pelvic Floor Institute
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

NCT00659646
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge and levofloxacin, Levofloxacin only
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lakeland, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 2 Interventional

Investigator-Sponsored Protocol - Continued Use of Ibalizumab

NCT01056393
View directory record Official record
Conditions
HIV Infections
Interventions
ibalizumab 800mg Q2Weeks, ibalizumab 2000mg Q4Weeks
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Jul 20, 2026, 7:31 PM EDT
Not listed No phase listed Observational

Bictegravir in the Elderly Living With HIV (BICEP)

NCT05064020
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 20, 2026, 7:31 PM EDT
Not yet recruiting Not applicable Interventional

Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs

NCT07631559
View directory record Official record
Conditions
HEPATITIS C (HCV), Opioid Use Disorder, Substance Use Disorder (SUD), Drug Use Disorders, Healthcare Access, Harm Reduction
Interventions
Partner navigation intervention booster session
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 20, 2026, 7:31 PM EDT
Withdrawn Phase 1 Interventional

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

NCT02378922
View directory record Official record
Conditions
AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma
Interventions
Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 66 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

NCT01595529
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Cefixime, Cephalexin, Placebo, Trimethoprim/Sulfamethoxazole
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 10 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Jul 20, 2026, 7:31 PM EDT
Completed No phase listed Observational Results available

Hepatitis C Pharmacy-based Strategy for Injectors

NCT04698629
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Not applicable Interventional

Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

NCT00002031
View directory record Official record
Conditions
HIV Infections
Interventions
Dinitrochlorobenzene
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 1 Interventional

Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum

NCT01914731
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal Microbiota Transplant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Jul 20, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Jul 20, 2026, 7:31 PM EDT